TNF and psoriasis: Whereas, elevated M. tuberculosis infection rates have been reported in association with anti-TNFα therapies in subjects with psoriasis and rheumatoid conditions,9, 10, 11, 12, 13 the low risk for TB reactivation upon secukinumab treatment in subjects with a medical history of TB or LTBI is further supported experimentally by the in vitro findings in a novel M. tuberculosis H37Rv three-dimensional microgranuloma model comparing adalimumab and secukinumab side by side.